Boehringer Ingelheim
For Healthcare Professionals
x

Registration Form

Information you provide when registering will be shared with the account owner and host and can be used and shared by them in accordance with their Terms and Privacy Policy.

Document ID: PC-MY-102220

Speaker: Prof. Jin-Hyoung Kang

Taking Cancer On Webinar – Let’s TOAST to Maximising Time on EGFR-TKI Therapy (Lecture)

Watch Prof. Jin-Hyoung Kang as he discusses how sequential approach with upfront GIOTRIF® (afatinib) is a feasible and cost-effective treatment strategy for EGFR M+ NSCLC patients.

Speaker

Prof-Jin-Hyoung-Kang-Image.png

Prof. Jin-Hyoung Kang

Professor of Medicine, Seoul St. Mary’s Hospital Director in Medical Oncology Program, The Catholic University of Korea Seoul, South Korea

RELATED CONTENT